Moderna Valuation
| MRNA Stock | USD 41.01 0.14 0.34% |
At this time, the firm appears to be overvalued. Moderna secures a last-minute Real Value of $35.39 per share. The latest price of the firm is $41.01. Our model forecasts the value of Moderna from analyzing the firm fundamentals such as Return On Equity of -0.29, current valuation of 12.2 B, and Profit Margin of (1.40) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Moderna's valuation include:
Price Book 1.7116 | Enterprise Value | Enterprise Value Ebitda 4.6412 | Price Sales 7.1792 | Forward PE 32.4675 |
Overvalued
Today
Please note that Moderna's price fluctuation is not too volatile at this time. Calculation of the real value of Moderna is based on 3 months time horizon. Increasing Moderna's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Moderna is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Moderna Stock. However, Moderna's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 41.01 | Real 35.39 | Target 38.8 | Hype 39.2 | Naive 33.68 |
The real value of Moderna Stock, also known as its intrinsic value, is the underlying worth of Moderna Company, which is reflected in its stock price. It is based on Moderna's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Moderna's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Moderna helps investors to forecast how Moderna stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Moderna more accurately as focusing exclusively on Moderna's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Moderna's intrinsic value based on its ongoing forecasts of Moderna's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Moderna's closest peers. If more than one evaluation category is relevant for Moderna we suggest using both methods to arrive at a better estimate.
Moderna Cash |
|
Moderna Total Value Analysis
Moderna is now estimated to have valuation of 12.2 B with market capitalization of 16.02 B, debt of 747 M, and cash on hands of 8.35 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Moderna fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
12.2 B | 16.02 B | 747 M | 8.35 B |
Moderna Investor Information
About 71.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.71. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Moderna recorded a loss per share of 8.06. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 3rd of August 2017. Based on the key measurements obtained from Moderna's financial statements, Moderna may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Moderna Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Moderna has an asset utilization ratio of 22.62 percent. This suggests that the Company is making $0.23 for each dollar of assets. An increasing asset utilization means that Moderna is more efficient with each dollar of assets it utilizes for everyday operations.Moderna Profitability Analysis
Based on the key profitability measurements obtained from Moderna's financial statements, Moderna may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Moderna's ability to earn profits and add value for shareholders.Net Loss | First Reported 2016-12-31 | Previous Quarter -825 M | Current Value -200 M | Quarterly Volatility 1.6 B |
For Moderna profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Moderna to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Moderna utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Moderna's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Moderna over time as well as its relative position and ranking within its peers.
Moderna Earnings per Share Projection vs Actual
The next projected EPS of Moderna is estimated to be -1.706325 with future projections ranging from a low of -2.015 to a high of -1.1175. Moderna's most recent 12-month trailing earnings per share (EPS TTM) is at -8.06. Please be aware that the consensus of earnings estimates for Moderna is based on EPS before non-recurring items and includes expenses related to employee stock options.Moderna Earnings Estimation Breakdown
The calculation of Moderna's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Moderna is estimated to be -1.706325 with the future projection ranging from a low of -2.015 to a high of -1.1175. Please be aware that this consensus of annual earnings estimates for Moderna is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-2.02 Lowest | Expected EPS | -1.12 Highest |
Moderna Earnings Projection Consensus
Suppose the current estimates of Moderna's value are higher than the current market price of the Moderna stock. In this case, investors may conclude that Moderna is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Moderna's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 24 | 66.66% | 0.0 | -1.706325 | -8.06 |
Moderna Ownership Allocation
Moderna maintains a total of 390.73 Million outstanding shares. The majority of Moderna outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Moderna to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Moderna. Please pay attention to any change in the institutional holdings of Moderna as this could imply that something significant has changed or is about to change at the company. On September 12, 2025, Representative Ro Khanna of US Congress acquired under $15k worth of Moderna's common stock.Moderna Profitability Analysis
The company reported the previous year's revenue of 3.2 B. Net Loss for the year was (3.56 B) with loss before overhead, payroll, taxes, and interest of (2.4 B).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Moderna's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Moderna and how it compares across the competition.
About Moderna Valuation
The stock valuation mechanism determines Moderna's current worth on a weekly basis. Our valuation model uses a comparative analysis of Moderna. We calculate exposure to Moderna's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Moderna's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2 B | 3.3 B | |
| Pretax Profit Margin | (1.01) | (1.07) | |
| Operating Profit Margin | (1.11) | (1.17) | |
| Net Loss | (1.00) | (1.05) | |
| Gross Profit Margin | 0.49 | 0.29 |
Moderna Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 384 M | |
| Quarterly Earnings Growth Y O Y | -0.851 | |
| Forward Price Earnings | 32.4675 |
Moderna Current Valuation Indicators
Valuation refers to the process of determining the present value of Moderna and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Moderna we look at many different elements of the entity such as Moderna's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Moderna, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Moderna's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Moderna's worth.Complementary Tools for Moderna Stock analysis
When running Moderna's price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |